Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 17/20 | 0.61 |
| ▸ | DRD3 | P35462 | 16/20 | 0.61 |
| ▸ | HRH1 | P35367 | 9/20 | 0.61 |
| ▸ | DRD2 | P14416 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2307186 | 0.97 | KCNH2 (0.60) | KCNH2DRD3HRH1DRD2 | |
| SCHEMBL17712726 | 0.80 | DRD3 (0.48) | KCNH2DRD3HRH1DRD2 | |
| SCHEMBL2285841 | 0.80 | DRD3 (0.42) | KCNH2DRD3HRH1DRD2 | |
| SCHEMBL2316059 | 0.77 | DRD3 (1.00) | KCNH2DRD3HRH1 | |
| SCHEMBL12377969 | 0.77 | DRD3 (0.56) | KCNH2DRD3HRH1DRD2 | |
| Hydrochloric Acid SCHEMBL2307467 | 0.76 | DRD3 (0.98) | KCNH2DRD3HRH1 | |
| SCHEMBL4385569 | 0.76 | DRD2 (0.71) | DRD3HRH1DRD2 | |
| SCHEMBL14077011 | 0.76 | DRD3 (0.44) | KCNH2DRD3HRH1DRD2 | |
| SCHEMBL378384 | 0.75 | KCNH2 (1.00) | KCNH2DRD3HRH1DRD2 | |
| SCHEMBL5245984 | 0.75 | KCNH2 (1.00) | KCNH2DRD3HRH1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| CN-101291669-B | Use of azabicyclo hexane derivatives | GLAXO GROUP LTD | 2012-09-26 | — | — | CN | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| EP-1773844-A1 | COMPOUNDS HAVING AFFINITY FOR THE DOPAMINE D3 RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | disclosed |
| EP-1758890-A1 | 7-PYRAZOLYLBENZAZEPINES HAVING AFFINITY FOR D3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-03-07 | — | — | EP | disclosed |
| WO-2007022980-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| EP-1751163-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006002928-A1 | COMPOUNDS HAVING AFFINITY FOR THE DOPAMINE D3 RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005123717-A1 | 7-PYRAZOLYLBENZAZEPINES HAVING AFFINITY FOR D3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005118549-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | DRD3, DRD1, DRD2 | KCNH2 192/4885DRD3 1/4885HRH1 92/4885 |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HTT, GBA2, GBA1 | KCNH2 4867/4885DRD3 1131/4885HRH1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.